Ketamine is under clinical development by Freedom Biosciences and currently in Phase II for Depression. According to GlobalData, Phase II drugs for Depression have a 43% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Ketamine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Ketamine overview
FREE-001 is under development for the treatment of depression. It is a ketamine-specific program, which acts by targeting N-methyl-D-aspartate (NMDA) receptor.
Freedom Biosciences overview
Freedom Biosciences is a biotechnology company engaged in developing psychedelic therapeutics. Freedom Biosciences is headquartered in San Francisco, California, the US.
For a complete picture of Ketamine’s drug-specific PTSR and LoA scores, buy the report here.
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.
